Cell surface terminal β-galactose-containing glycans

Cell surface terminal β-galactose-containing glycans are carbohydrate structures found on the surface of cells, where a galactose residue is positioned at the non-reducing terminus of a glycan chain via a β-linkage (NIH, 2020). These glycans serve as essential recognition motifs for a variety of endogenous and exogenous proteins, including the galectin family of lectins and the hepatic asialoglycoprotein receptor (ASGPR) (ACS, 2012; NIH, 2025). In normal physiology, they play pivotal roles in cell-cell adhesion, signal transduction, and the homeostatic clearance of desialylated serum glycoproteins by the liver (Wikipedia, 2024). In pathological contexts, such as cancer, these glycans are often overexpressed or exposed due to altered glycosylation patterns, such as the Thomsen-Friedenreich antigen, where they facilitate tumor metastasis, angiogenesis, and immune evasion by forming lattices with galectins (ACS, 2012; NIH, 2025). Therapeutically, they are targeted by glycan-binding antibodies and toxins, and they are widely exploited as targeting ligands in drug delivery systems to achieve hepatocyte-specific uptake of therapeutic payloads, including nucleic acids and small molecules (NIH, 2025). The interaction between these glycans and their receptors is highly sensitive to the density and spatial arrangement of the galactose residues, a property utilized in the design of multivalent glycomimetic drugs (NIH, 2026). Furthermore, the presence of terminal galactose on therapeutic antibodies can significantly modulate their effector functions, such as antibody-dependent cell-mediated cytotoxicity (ADCC), by influencing their affinity for Fc receptors (NIH, 2020).

Other names

Terminal beta-galactose residuesGalactose-terminated glycansAsialoglycansβ-galactoside-containing glycansThomsen-Friedenreich antigenTF antigenGal-terminated glycansAsialoglycoprotein receptor ligands

Competitive inhibition of lectin-glycan interactions, receptor-mediated endocytosis via the asialoglycoprotein receptor, direct cell-surface binding and internalization, and modulation of immune effector functions such as antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).